Nxera Pharma
Manufacturing · Japan · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Pmo Hanzomon 11TH Fl 2-1, Tokyo, Tokyo, ...Phone Number
+81 352103290Website
nxera.lifeRevenue
$103.5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Nxera Pharma
Nxera Pharma is dedicated to accelerating the development of life-changing medicines through investments in science and technology. Utilizing their proprietary NxWave platform, they focus on rational structure-based drug design to unlock the potential of GPCRs. The company aims to provide better treatment options for patients in need and is actively pursuing groundbreaking discoveries in the pharmaceutical field. Their commitment to innovation positions them as a leader in the development of transformative therapies.Explore more
Popular SearchesNxera Pharma Co. LtdNxera Pharma Co LtdNxera PharmaNxera Pharma CoNxera Pharma Korea Co LtdSIC Code 28,283NAICS Code 32,325Show moreNxera Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nxera Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Nxera Pharma
Funding: Get notified immidiatlly once Nxera Pharma has new funding data
Check if Nxera Pharma has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if Nxera Pharma had a recent Job posting/layoffs
Product Launch: Get notified when Nxera Pharma launches new products
Nxera Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Nxera Pharma is spiking on competitors!
Earning: See what the market has to say on Nxera Pharma recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Nxera Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nxera Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nxera Pharma.
Nxera Pharma Tech Stack
A closer look at the technologies used by Nxera Pharma
Most Recent Scoops
Project
, according to a high-level source in diversity & inclusion, has completed initiatives related to manager self-service (MSS) within the last twelve months.
HRIS, Employee Relations, Enterprise Software, Software, Workforce Management, Company Culture & Policy, Diversity & Inclusion
Project
, according to a high-level source in diversity & inclusion, is in the midst of initiatives related to talent management. The organization is currently evaluating Workday.
Employee Relations, Company Culture & Policy, Diversity & Inclusion, HR Operations, Talent Management
Project
, according to a high-level source in diversity & inclusion, is in the midst of initiatives related to applicant tracking systems (ATS). The organization is currently evaluating various vendors.
HRIS, Employee Relations, Enterprise Software, Recruitment, Software, Company Culture & Policy, Diversity & Inclusion, HR Operations, Talent Acquisition
Project
, according to a high-level source in diversity & inclusion, is in the midst of initiatives related to succession management. The organization is currently evaluating various vendors.
Employee Relations, Workforce Management, Company Culture & Policy, Diversity & Inclusion, HR Operations
Project
Training, Learning & Development, Employee Relations, Software, Learning Management Systems (LMS), Company Culture & Policy, Diversity & Inclusion
Nxera Pharma News & Media
Nxera Pharma Webinar for Financial Results Presentation - 2Q2026
Tokyo, Japan and Cambridge and London, UK, 15 July 2026 – Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for 2Q 2026 on Friday, 7 August 2026. The Company will host a live webinar presentation with Chris Cargill (President, CEO), Hironoshin Nomura (CFO), Toshi Maeda (COO) and Patrik Foerch (CSO and President of Nxera Pharma UK), at 5:00 pm JST (9:00 am GMT) on Friday, 7 AugustNxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
Tokyo, Japan and Cambridge and London, UK, 30 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a fourth R&D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a payment of US$10 million to Nxera.Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery
Tokyo, Japan and Cambridge, UK, 10 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that it has joined OpenFold, a non-profit AI research consortium that promotes the development of open-source AI software tools for biology and drug discovery. Technology companies, including Amazon Web Services, Microsoft and NVIDIA, participate in OpenFold as supporting members and the consortium has expanded into an international ecosystem comprising numerous pharmaceutical companies, biNxera’s Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea
Tokyo, Japan and Cambridge, UK, 2 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation to vamorolone for the treatment of Duchenne muscular dystrophy (DMD). The Company plans to submit a Marketing Authorization Application (MAA) for vamorolone in South Korea during 2026.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nxera Pharma
Sign Up For FreeTo access detailed company insights
Nxera Pharma is dedicated to accelerating the development of life-changing medicines through investments in science and technology. Utilizing their proprietary NxWave platform, they focus on rational structure-based drug design to unlock the potential of GPCRs. The company aims to provide better treatment options for patients in need and is activel... Read More
